Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 3. The women's health initiative: Unopposed estrogen

Journal of Family Planning and Reproductive Health Care

Volumn 37, Issue 4, 2011, Pages 225-230

  Shapiro, Samuel ^a   Farmer, Richard D T ^b   Mueck, Alfred O ^c   Seaman, Helen ^d   Stevenson, John C ^e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d London and Royal Brompton Hospital ^*

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; PLACEBO;

ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL (TOPIC); FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MENOPAUSE; RISK ASSESSMENT; TREATMENT RESPONSE;

BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; CAUSALITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG COMBINATIONS; EPIDEMIOLOGIC RESEARCH DESIGN; EPIDEMIOLOGIC STUDIES; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 81055123602     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc-2011-0091     Document Type: Article

References (37)

1. Shapiro S, Farmer RDT, Seaman H, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 1. The Collaborative Reanalysis. J Fam Plann Reprod Health Care 2011;37:103-109.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059.
3. Shapiro S, Farmer RDT, Mueck AO, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 2. The Women's Health Initiative: estrogen plus progestogen. J Fam Plann Reprod Health Care 2011;37(in press).
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
5. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253. (Pubitemid 37430077)
6. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-115. (Pubitemid 44307491)
7. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045. (Pubitemid 351347060)
8. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008;167:1207-1216. (Pubitemid 351670642)
9. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-587.
10. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12-23.
11. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-1692.
12. Hill AB. The environment and disease: association or causation? Proc Royal Soc Med 1965;58:295-300.
13. Susser M. Causal Thinking in the Health Sciences. New York, NY: Oxford University Press, 1979.
14. Department of Health, Education and Welfare. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: U.S. Government Printing Office, 1964.
15. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
16. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-1657.
17. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-1314.
18. Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008;167:1407-1415.
19. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
20. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-1674. (Pubitemid 46631679)
21. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-375.
22. McTiernan A, Chlebowski RT, Martin C, et al. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol 2009;27:6135-6143.
23. Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000;151:939-945.
24. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005;20:2052-2060. (Pubitemid 41418488)
25. Mueck AO, Seeger H, Shapiro S. Risk of breast cancer during hormone replacement therapy: mechanisms. Horm Biol Clin Invest 2010;3:329-339.
26. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:s1-s66.
27. Lippert TH, Seeger H, Mueck AO. Pharmacology and toxicology of different estrogens. Gynecol Endocrinol 2001;15(Suppl 4):26-33. (Pubitemid 33731454)
28. International Agency for Research on Cancer. Monographs on the Evaluation of the Carcinogenic Risks to Humans: Hormonal Contraception and Postmenopausal Hormone Therapy. Lyon, France: IARC, 1999;72:474-530.
29. Seeger H, Wallwiener D, Kraemer E, et al. Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 2006;54:72-77.
30. Lewis-Wambi JS, Jordan VC. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 2009;11:206.
31. Maximov F, Sengupta S, Joan S, et al. The confirmation of the estrogen receptor directs estrogen-induced apoptosis in breast cancer: a hypothesis. Horm Mol Biol Clin Invest 2011;5:27-34.
32. Munster PN, Carpenter JT. Estradiol in breast cancer treatment: reviving the past. JAMA 2009;302:797-798.
33. Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009;302:774-780.
34. Mueck AO, Seeger H. 2-Methoxyestradiol - biology and mechanism of action. Steroids 2010;75:625-631.
35. Shapiro S. Re: "Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study". Am J Epidemiol 2008;168:1213; author reply 1213-1213; author reply 1214.
36. Prentice RL, Chlebowski RT, Rossouw JE, et al. Four authors reply [Letter to the Editor]. Am J Epidemiol 2008;168: 1213-1214.
37. Shapiro S. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric 2004;7:3-7. (Pubitemid 38367157)